The ERISA Industry Committee Applauds FDA Efforts to Make Biosimilars More Accessible
August 21, 2024
August 21, 2024
WASHINGTON, Aug. 21 (TNSres) -- The ERISA Industry Committee issued the following news release on Aug. 20, 2024:
The ERISA Industry Committee (ERIC) today praised draft guidance (https://www.fda.gov/media/179456/download) (Guidance) by the U.S. Food and Drug Administration (FDA) that will help increase competition in the prescription drug markets, boosting the availability of affordable biosimilar drugs. The Guidance removes the FDA switching study requirement and provides updated r . . .
The ERISA Industry Committee (ERIC) today praised draft guidance (https://www.fda.gov/media/179456/download) (Guidance) by the U.S. Food and Drug Administration (FDA) that will help increase competition in the prescription drug markets, boosting the availability of affordable biosimilar drugs. The Guidance removes the FDA switching study requirement and provides updated r . . .